REFERENCES
- Hovind P, Tarnow L, Rossing K, . Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care. 2003;26:1258–1264.
- Bloomgarden ZT. Diabetic nephropathy. Diabetes Care. 2005;28:745–751.
- Brenner BM, Cooper ME, de Zeeuw D, . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
- Lewis EJ, Hunsicker LG, Clarke WR, . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
- The Diabetes Control and Complications Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int. 1995;47:1703–1720.
- Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol. 2005;16:S30–S33.
- Eddy AA. Progression in chronic kidney disease. Adv Chronic Kidney Dis. 2005;12:353–365.
- Schnaper HW, Hayashida T, Hubchak SC, Pobcelet AC. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol. 2003;284:F243–F252.
- Rutter GA, Silva Xavier DA, Leclerc I. Roles of 5-AMP-activated protein kinase (AMPK) in mammalian glucose homoeostasis. Biochem J. 2003;375:1–16.
- Myung-Ja L, Denis F, Meenalakshmi MM, . A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 2007;292:F617–F627.
- Hiroyuki M, Barry JG, Motoyuki I, Eiichi A. AMPK and cell proliferation—AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol. 2006;574:63–71.
- Hardie DG. The AMP-activated protein kinase pathway—New players upstream and downstream. J Cell Sci. 2004;117:5479–5487.
- Park SH, Gammon SR, Knippers JD, . Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle. J Appl Physiol. 2002;92:2475–2482.
- Liu Y, Wan Q, Guan QB, Gao L, Zhao JJ. High-fat diet feeding impairs both the expression and activity of AMPKa in rats’ skeletal muscle. Biochem Biophys Res Commun. 2006;339:701–707.
- Bieke FS, De Vriese AS, Flyvbjerg A. From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocrinol Rev. 2004;25:971–1010.
- Myung JL, Denis F, Mariappan M, . A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Renal Physiol. 2007;292:F617–F627.
- Philippe GC, Irene L, Gingras D, Bendayan M. Control of glycogen synthase through ADIPOR1-AMPK pathway in renal distal tubules of normal and diabetic rats. Am J Physiol Renal Physiol. 2008;294:F881–F889.
- Wyatt M, Zanescu DI, Sood V, Beale EG, Prabhakar SS. The role of 5’-AMP-activated protein kinase (AMPK) in diabetic nephropathy: A new direction? Curr Enzyme Inhib. 2009;5:44–50.
- Eduardo RR, José RP, Maria Fernanda AF, . A central role for neuronal AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) in high-protein diet–induced weight loss. Diabetes. 2008;57:594–605.
- Feng L, Gao L, Guan QB, . Long-term moderate ethanol consumption restores insulin sensitivity in high-fat-fed rats by increasing GLUT4 in the adipose tissue by AMPK activation. J Endocrinol. 2008;199:95–104.
- Salt IP, Johnson G, Ashcroft SJ, Hardie DG. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. Biochem J. 1998;335:533–539.
- Cammisotto PG, Bendayan M. Adiponectin stimulates phosphorylation of AMP-activated protein kinase alpha in renal glomeruli. J Mol Histol. 2008;39:579–584.
- Yi L, Lei J, Zun CL, . Emodin ameliorates high-glucose induced mesangial p38 over-activation and hypocontractility via activation of PPARγ. Exp Mol Med. 2009;41:648–655.
- Wang R, Wan Q, Zhang Y, . Emodin suppresses interleukin-1beta induced mesangial cells proliferation and extracellular matrix production via inhibiting p38 MAPK. Life Sci. 2007;80:2481–2488.